Funding
← Back to your selection

Bpifrance

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026

Bpifrance is France’s public investment bank, financing businesses through equity, loans and guarantees and supporting innovation and international expansion.

Its equity activity includes venture capital, growth investment and investments in other funds. Innovation financing can also support research, development and bringing a product to market, so founders may have financing options beyond a conventional equity round.

The appropriate route depends on the project and stage: research funding, a guarantee for borrowing, direct investment and export support serve different needs. Its bank-for-entrepreneurs model connects those instruments with programmes for developing a French business.

Sources
Rounds participated in
8
Confirmed lead rounds
0
5 roles undisclosed
New companies
8
First participation on record · 0 follow-on
Funding in participating rounds
$153.3M
5 disclosed · full round size, not this investor’s share

By stage

Series A3
Seed2
Series C+2
Undisclosed1

By primary sector

Biotech6
Foodtech2

By country

France6
Denmark1
Switzerland1

Rounds

8 in this selection
Nouscom

Clinical-stage biotech developing neoantigen-based cancer immunotherapies.

€120MSeries D
Participant
Edonia

French foodtech company making protein-rich ingredients from spirulina.

€15MSeries A financing package including non-dilutive and bank funding
Participant
One Biosciences

Single-cell tumour profiling for oncology teams and pharma and biotech partners, turning routine biopsy samples into clinical insights for treatment selection and drug development.

€3.3Mi-Démo 5 grant (France 2030)
Participant
Brenus Pharma

Develops an off-the-shelf in vivo immunotherapy platform for solid tumors

€11MSeries A
Role not disclosed
Lys Therapeutics

Develops monoclonal antibody LYS241 targeting neurovascular pathways for Parkinson's disease and stroke

Role not disclosed
Adcendo

Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.

$75MSeries C
Role not disclosed
Verley

Develops functional whey protein ingredients through precision fermentation for food and nutrition manufacturers

€32MSeries A
Role not disclosed
Enodia Therapeutics

Develops small-molecule therapies for targeted protein degradation at the point of synthesis

Role not disclosed